Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 30 for

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

    Rochester, MN

  2. Safety and Efficacy of B-cell Activating Factor Receptor (BAFFR)-based Chimeric Antigen Receptor T-cells in Subjects with Relapsed or Refractory BAFFR-expressing B-cell Hematologic Malignancies

    Jacksonville, FL

  3. A Study to Evaluate the Safety and Effectiveness of Lisocatagene Maraleucel in Patients

    Jacksonville, FL, Rochester, MN

  4. A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

    Jacksonville, FL, Rochester, MN

  5. Exploring the Role of B-cell Activating Factor Receptor (BAFFR)-based Chimeric Antigen Receptor T-cell (CAR T) in BAFFR-expressing B-cell Hematologic Malignancies and Autoimmune Rheumatologic Disorders

    Jacksonville, FL

  6. Manufacturing Outcomes with Patient Factors from Multiple Myeloma Patients Prescribed Ciltacabtagene Autoleucel

    Rochester, MN

  7. A2B101-101: Obtaining Solid Tumor Tissue from Subjects Having Surgical Resection for Certain Tumor Types and Leukapheresis for CAR T-cell Therapy Manufacturing

    Rochester, MN, Jacksonville, FL, Scottsdale/Phoenix, AZ

  8. Innovative CAR-TIL immunotherapy against melanoma

    Jacksonville, FL

  9. Bispecific Aptamer Engagers for Cancer Therapy

    Jacksonville, FL

  10. Assessing the Psychosocial and Financial Impact of CAR-T on Survivors and Caregivers

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer